Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 Dose Escalating, Double-Blind, Randomized Comparator Controlled Trial of the Safety andImmunogenicity of Pfs25M-EPA/AS01 and Pfs230D1M-EPA/AS01 Vaccines, Transmission Blocking Vaccines Against Plasmodium Falciparum at Full and Fractional Dosing in Adults in Mali

Next Previous
X
Search
Trial Profile

Phase 1 Dose Escalating, Double-Blind, Randomized Comparator Controlled Trial of the Safety andImmunogenicity of Pfs25M-EPA/AS01 and Pfs230D1M-EPA/AS01 Vaccines, Transmission Blocking Vaccines Against Plasmodium Falciparum at Full and Fractional Dosing in Adults in Mali

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 31 Jan 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pfs25 malaria vaccine MVI (Primary) ; Pfs25 Pfs230 malaria vaccine MVI (Primary) ; Artemether/lumefantrine; AS01B; Hepatitis B vaccine recombinant; Meningococcal vaccine groups A C Y W-135 conjugate
  • Indications Malaria
  • Focus Adverse reactions

    • Most Recent Events

    • 16 Jul 2020 Status changed from active, no longer recruiting to completed.
    • 12 Feb 2020 Planned End Date changed from 31 Jan 2020 to 31 Jan 2021.
    • 12 Feb 2020 Planned primary completion date changed from 31 Jan 2020 to 31 Jan 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top